Zacks Research Brokers Reduce Earnings Estimates for Revvity

Key Points

• Zacks Research has lowered its Q3 2025 earnings estimate for Revvity to $1.14 per share from the previous estimate of $1.26.
• Several analysts have decreased their price targets for Revvity, with most recent targets between $110.00 and $115.00, while maintaining an average rating of "Moderate Buy."
• The company recently declared a quarterly dividend of $0.07 per share, with an annualized yield of 0.3%, reflecting a dividend payout ratio of 11.86%.

Revvity Inc. (NYSE:RVTY - Free Report) - Research analysts at Zacks Research lowered their Q3 2025 earnings per share estimates for shares of Revvity in a research note issued to investors on Wednesday, September 3rd. Zacks Research analyst Team now anticipates that the company will earn $1.14 per share for the quarter, down from their previous estimate of $1.26. The consensus estimate for Revvity's current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity's Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $4.86 EPS, Q1 2026 earnings at $1.12 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.61 EPS, FY2026 earnings at $5.35 EPS, Q1 2027 earnings at $1.25 EPS, Q2 2027 earnings at $1.49 EPS and FY2027 earnings at $6.08 EPS.

A number of other research analysts have also commented on RVTY. Raymond James Financial reissued an "outperform" rating and set a $115.00 price objective (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd. Evercore ISI lowered their price objective on Revvity from $116.00 to $115.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Bank of America lowered their target price on Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Stifel Nicolaus lowered their target price on Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a report on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $120.07.

Revvity Stock Performance

Shares of RVTY stock opened at $83.25 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.33 and a quick ratio of 2.75. The firm has a market cap of $9.66 billion, a P/E ratio of 35.28, a PEG ratio of 2.42 and a beta of 0.94. The stock's 50-day moving average is $93.55 and its two-hundred day moving average is $97.59. Revvity has a fifty-two week low of $82.04 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The company had revenue of $720.28 million for the quarter, compared to analyst estimates of $711.26 million. During the same period in the prior year, the firm posted $1.22 EPS. The business's revenue was up 4.1% compared to the same quarter last year. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be given a $0.07 dividend. The ex-dividend date is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity's dividend payout ratio (DPR) is currently 11.86%.

Institutional Trading of Revvity

A number of hedge funds have recently modified their holdings of the company. CYBER HORNET ETFs LLC bought a new position in shares of Revvity during the 2nd quarter worth approximately $32,000. MUFG Securities EMEA plc bought a new position in shares of Revvity during the 2nd quarter worth approximately $34,000. UMB Bank n.a. lifted its position in shares of Revvity by 138.8% during the 2nd quarter. UMB Bank n.a. now owns 406 shares of the company's stock worth $39,000 after buying an additional 236 shares during the period. CVA Family Office LLC lifted its position in shares of Revvity by 79.0% during the 2nd quarter. CVA Family Office LLC now owns 410 shares of the company's stock worth $40,000 after buying an additional 181 shares during the period. Finally, Vermillion Wealth Management Inc. bought a new position in shares of Revvity during the 4th quarter worth approximately $41,000. Institutional investors own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.